Based on these assumptions, in a Phase II trial, Lissoni and colleagues[85] treated metastatic RCC patients, who had already been on IL-2, with a combination of IL-2 and EPO (10,000 units, 3 times a week). Here, EPO is linked to renal cell carcinoma.